PhoenixBio Co., Ltd.
Stock Price Chart
2026/10/09 19:27 UpdatedPrice Trend
2026/10/09 19:27 UpdatedPrice & Trading Details
2026/10/09 19:27 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,124M | ¥1,715M | ¥1,541M | ¥1,566M |
| Gross Profit | ¥1,556M | ¥1,195M | ¥1,118M | ¥1,201M |
| Operating Income | ¥508M | ¥11M | -¥142M | ¥83M |
| Pretax Income | ¥514M | ¥63M | -¥428M | ¥136M |
| Net Income | ¥493M | ¥26M | -¥449M | ¥125M |
| EPS | ¥97.29 | ¥6.98 | -¥110.83 | ¥30.81 |
| Operating Margin | 23.94% | 0.65% | -9.22% | 5.29% |
| Balance Sheet | ||||
| Total Assets | ¥3,019M | ¥2,715M | ¥2,285M | ¥2,193M |
| Total Equity | ¥1,514M | ¥1,798M | ¥1,365M | ¥1,553M |
| Total Liabilities | ¥1,504M | ¥918M | ¥920M | ¥640M |
| Cash | ¥1,555M | ¥1,385M | ¥1,149M | ¥1,147M |
| Interest-bearing Debt | ¥1,130M | ¥724M | ¥565M | ¥487M |
| Equity Ratio | 50.17% | 66.20% | 59.75% | 70.81% |
| D/E Ratio | 0.75 | 0.40 | 0.41 | 0.31 |
| Cash Flow | ||||
| Operating CF | ¥277M | -¥79M | -¥73M | ¥69M |
| Investing CF | -¥156M | ¥115M | -¥28M | -¥14M |
| Financing CF | ¥87M | -¥245M | -¥128M | -¥88M |
| Free CF | ¥265M | -¥118M | -¥105M | ¥54M |
| Efficiency | ||||
| ROE | 32.57% | 1.47% | -32.88% | 8.07% |
| ROA | 16.34% | 0.97% | -19.64% | 5.71% |
Latest IR Information
-
Notice of Board Resolution Regarding Duplicate Listing Application to the Fukuoka Stock Exchange
Resolved to apply for listing on the Fukuoka Stock Exchange (Main Market). The objective is to raise awareness and improve liquidity mainly in the Kyushu region. Timelines and approval status are undecided, and notices will be provided as future disclosures.
Read more -
Plan for Achieving Compliance with Listing Continuation Criteria
Read more -
Plan for Compliance with Listing Maintenance Standards
Read more -
Matters Concerning Controlling Shareholders, Etc.
Read more -
Matters Concerning Controlling Shareholders, Etc.
Read more
Latest News (5 items)
Company Information
About
PhoenixBio Co., Ltd. provides contract testing services for medical product development in Japan, the United States, and internationally. The company offers PXB-mouse, a chimeric mouse with a humanized liver used in drug development experiments; and PXB-cells, human hepatocytes for in vitro studies and experiments, as well as HBV study services. Its products are used in gene therapeutics, MASH/MAFLD, viral hepatitis, DMPK/toxicity, and custom transplantations applications. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
